Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 52

1.

High rate of sustained virological response with direct-acting antivirals in haemophiliacs with HCV infection: A multicenter study.

Mancuso ME, Linari S, Santagostino E, Bartolozzi D, D'Ambrosio R, Borghi M, Lampertico P, Peyvandi F, Castaman G, Aghemo A.

Liver Int. 2019 Dec 26. doi: 10.1111/liv.14337. [Epub ahead of print]

PMID:
31876354
2.

Immune tolerance induction with moroctocog-alpha (Refacto/Refacto AF) in a population of Italian haemophilia A patients with high-titre inhibitors: Data from REF.IT Registry.

Zanon E, Pasca S, Pollio B, Santagostino E, Linari S, Tagliaferri A, Santoro C, Rocino A, Marino R, Aru B, Borchiellini A, Siragusa S, Coppola A.

Haemophilia. 2019 Nov;25(6):1003-1010. doi: 10.1111/hae.13859. Epub 2019 Oct 11.

PMID:
31603594
3.

TNF-α/TNF-R System May Represent a Crucial Mediator of Proliferative Synovitis in Hemophilia A.

Manetti M, Linari S, Romano E, Rosa I, Carulli C, Innocenti M, Matucci-Cerinic M, Ibba-Manneschi L, Castaman G, Melchiorre D.

J Clin Med. 2019 Jun 28;8(7). pii: E939. doi: 10.3390/jcm8070939.

4.

Physical activity improved by adherence to prophylaxis in an Italian population of children, adolescents and adults with severe haemophilia A: the SHAPE Study.

Zanon E, Tagliaferri A, Pasca S, Ettorre CP, Notarangelo LD, Biasioli C, Aru AB, Milan M, Linari S, Rocino A, Gagliano F, Di Minno G, Gamba G, Santoro RC, Schinco P, Marietta M, Seuser A, von Mackensen S.

Blood Transfus. 2019 Jun 5:1-6. doi: 10.2450/2019.0040-19. [Epub ahead of print]

5.

Functional polymorphisms in the LDLR and pharmacokinetics of Factor VIII concentrates.

Lunghi B, Bernardi F, Martinelli N, Frusconi S, Branchini A, Linari S, Marchetti G, Castaman G, Morfini M.

J Thromb Haemost. 2019 Aug;17(8):1288-1296. doi: 10.1111/jth.14473. Epub 2019 May 29.

PMID:
31055871
6.

Current and emerging biologics for the treatment of hemophilia.

Castaman G, Linari S.

Expert Opin Biol Ther. 2019 Aug;19(8):801-810. doi: 10.1080/14712598.2019.1614163. Epub 2019 May 9.

PMID:
31039049
7.

Prophylactic versus on-demand treatments for hemophilia: advantages and drawbacks.

Castaman G, Linari S.

Expert Rev Hematol. 2018 Jul;11(7):567-576. doi: 10.1080/17474086.2018.1486704. Epub 2018 Jun 19. Review.

PMID:
29886751
8.

Inhibitors in Nonsevere Hemophilia A: What Is Known and Searching for the Unknown.

Abdi A, Linari S, Pieri L, Voorberg J, Fijnvandraat K, Castaman G.

Semin Thromb Hemost. 2018 Sep;44(6):568-577. doi: 10.1055/s-0037-1621717. Epub 2018 Feb 13. Review.

PMID:
29439277
9.

Pharmacokinetic drug evaluation of recombinant factor VIII for the treatment of hemophilia A.

Castaman G, Linari S.

Expert Opin Drug Metab Toxicol. 2018 Feb;14(2):143-151. doi: 10.1080/17425255.2018.1420161. Epub 2017 Dec 27. Review.

PMID:
29257899
10.

Diagnosis and Treatment of von Willebrand Disease and Rare Bleeding Disorders.

Castaman G, Linari S.

J Clin Med. 2017 Apr 10;6(4). pii: E45. doi: 10.3390/jcm6040045. Review.

11.

European retrospective study of real-life haemophilia treatment.

Berntorp E, Dolan G, Hay C, Linari S, Santagostino E, Tosetto A, Castaman G, Álvarez-Román MT, Parra Lopez R, Oldenburg J, Albert T, Scholz U, Holmström M, Schved JF, Trossaërt M, Hermans C, Boban A, Ludlam C, Lethagen S.

Haemophilia. 2017 Jan;23(1):105-114. doi: 10.1111/hae.13111. Epub 2016 Oct 20.

PMID:
27761962
12.

A contribution to the debate about the possible different clinical severity between hemophilia A and B.

Melchiorre D, Linari S, Matucci-Cerinic M, Castaman G.

Haematologica. 2016 Oct;101(10):e430. No abstract available.

14.

Human von Willebrand factor/factor VIII concentrates in the management of pediatric patients with von Willebrand disease/hemophilia A.

Castaman G, Linari S.

Ther Clin Risk Manag. 2016 Jun 30;12:1029-37. doi: 10.2147/TCRM.S87543. eCollection 2016. Review.

15.

Emerging Issues in Diagnosis, Biology, and Inhibitor Risk in Mild Hemophilia A.

Castaman G, Eckhardt C, van Velzen A, Linari S, Fijnvandraat K.

Semin Thromb Hemost. 2016 Jul;42(5):507-12. doi: 10.1055/s-0036-1571309. Epub 2016 May 5. Review.

PMID:
27148839
16.

Standardization of MRI and Scintigraphic Scores for Assessing the Severity of Bone Marrow Involvement in Adult Patients With Type 1 Gaucher Disease.

Mariani G, Perri M, Minichilli F, Ortori S, Linari S, Giona F, Di Rocco M, Cappellini MD, Guidoccio F, Erba PA.

AJR Am J Roentgenol. 2016 Jun;206(6):1245-52. doi: 10.2214/AJR.15.15294. Epub 2016 Apr 8.

PMID:
27057587
17.

Clinical manifestations and management of Gaucher disease.

Linari S, Castaman G.

Clin Cases Miner Bone Metab. 2015 May-Aug;12(2):157-64. doi: 10.11138/ccmbm/2015.12.2.157. Epub 2015 Oct 26. Review.

18.

Cancers in Patients with von Willebrand Disease: A Survey from the Italian Association of Haemophilia Centres.

Franchini M, Di Perna C, Santoro C, Castaman G, Siboni SM, Zanon E, Linari S, Gresele P, Pasca S, Coppola A, Santoro R, Napolitano M, Ranalli P, Tagliaferri A; Italian Association of Haemophilia Centres.

Semin Thromb Hemost. 2016 Feb;42(1):36-41. doi: 10.1055/s-0035-1564844. Epub 2015 Nov 23.

PMID:
26595151
19.

Hematological manifestations and complications of Gaucher disease.

Linari S, Castaman G.

Expert Rev Hematol. 2016 Jan;9(1):51-8. doi: 10.1586/17474086.2016.1112732. Epub 2015 Nov 13. Review.

PMID:
26565753
20.

Clinical, instrumental, serological and histological findings suggest that hemophilia B may be less severe than hemophilia A.

Melchiorre D, Linari S, Manetti M, Romano E, Sofi F, Matucci-Cerinic M, Carulli C, Innocenti M, Ibba-Manneschi L, Castaman G.

Haematologica. 2016 Feb;101(2):219-25. doi: 10.3324/haematol.2015.133462. Epub 2015 Oct 22.

21.

Total Hip Arthroplasty in Haemophilic Patients with Modern Cementless Implants.

Carulli C, Felici I, Martini C, Civinini R, Linari S, Castaman G, Innocenti M.

J Arthroplasty. 2015 Oct;30(10):1757-60. doi: 10.1016/j.arth.2015.04.035. Epub 2015 May 5.

PMID:
25998131
22.

Patient preference and ease of use for different coagulation factor VIII reconstitution device scenarios: a cross-sectional survey in five European countries.

Cimino E, Linari S, Malerba M, Halimeh S, Biondo F, Westfeld M.

Patient Prefer Adherence. 2014 Dec 12;8:1713-20. doi: 10.2147/PPA.S64709. eCollection 2014. Erratum in: Patient Prefer Adherence. 2015;9:243.

23.

Long term effects of enzyme replacement therapy in an Italian cohort of type 3 Gaucher patients.

Sechi A, Deroma L, Dardis A, Ciana G, Bertin N, Concolino D, Linari S, Perria C, Bembi B.

Mol Genet Metab. 2014 Nov;113(3):213-8. doi: 10.1016/j.ymgme.2014.07.022. Epub 2014 Aug 4.

PMID:
25127542
24.

Interferon lambda 3 rs12979860 polymorphism in patients with haemophilia and HCV infection: a predictor of spontaneous viral clearance and sustained virological response.

Mancuso ME, Linari S, Aghemo A, Bartolozzi D, Santagostino E, Rumi MG, Fognani E, Fasulo MR, Gragnani L, Bruno R, Morfini M, Zignego AL, Colombo M.

Thromb Haemost. 2014 Jun;111(6):1067-76. doi: 10.1160/TH13-11-897. Epub 2014 Feb 13.

PMID:
24522196
25.

Agonistic anti-human Fas monoclonal antibody induces fibroblast-like synoviocyte apoptosis in haemophilic arthropathy: potential therapeutic implications.

Romano E, Manetti M, Peruzzi F, Melchiorre D, Milia AF, Bellando-Randone S, Nishioka K, Innocenti M, Carulli C, Linari S, Morfini M, Ibba-Manneschi L, Matucci-Cerinic M, Guiducci S.

Haemophilia. 2014 Jan;20(1):e32-9. doi: 10.1111/hae.12304. Epub 2013 Nov 20.

PMID:
24308756
26.

Anti-TNF-α therapy prevents the recurrence of joint bleeding in haemophilia and arthritis.

Melchiorre D, Morfini M, Linari S, Zignego AL, Innocenti M, Matucci Cerinic M.

Rheumatology (Oxford). 2014 Mar;53(3):576-8. doi: 10.1093/rheumatology/ket280. Epub 2013 Oct 17. No abstract available.

PMID:
24136067
27.

Prevalence of hemostatic disorders in adolescents with abnormal uterine bleeding.

Seravalli V, Linari S, Peruzzi E, Dei M, Paladino E, Bruni V.

J Pediatr Adolesc Gynecol. 2013 Oct;26(5):285-9. doi: 10.1016/j.jpag.2013.06.003.

PMID:
24012130
28.

99mTc-sestamibi scintigraphy to monitor the long-term efficacy of enzyme replacement therapy on bone marrow infiltration in patients with Gaucher disease.

Erba PA, Minichilli F, Giona F, Linari S, Dambrosia J, Pierini A, Filocamo M, Di Rocco M, Buffoni F, Brady RO, Mariani G.

J Nucl Med. 2013 Oct;54(10):1717-24. doi: 10.2967/jnumed.113.121871. Epub 2013 Aug 29.

29.

Are the standard definitions of osteopenia and osteoporosis appropriate for coinfected patients with haemophilia?

Linari S, Montorzi G, Borderi M, Bartolozzi D, Melchiorre D, Morfini M.

Haemophilia. 2013 Sep;19(5):e316-8. doi: 10.1111/hae.12207. Epub 2013 Jun 19. No abstract available.

PMID:
23781867
30.

Minimal disease activity in Gaucher disease: criteria for definition.

Di Rocco M, Andria G, Bembi B, Carubbi F, Giona F, Giuffrida G, Linari S, Sibilio M, Spina V, Cappellini MD.

Mol Genet Metab. 2012 Nov;107(3):521-5. doi: 10.1016/j.ymgme.2012.08.009. Epub 2012 Aug 17.

PMID:
22954583
31.

Hypovitaminosis D and osteopenia/osteoporosis in a haemophilia population: a study in HCV/HIV or HCV infected patients.

Linari S, Montorzi G, Bartolozzi D, Borderi M, Melchiorre D, Benelli M, Morfini M.

Haemophilia. 2013 Jan;19(1):126-33. doi: 10.1111/j.1365-2516.2012.02899.x. Epub 2012 Jul 9.

PMID:
22776099
32.

RANK-RANKL-OPG in hemophilic arthropathy: from clinical and imaging diagnosis to histopathology.

Melchiorre D, Milia AF, Linari S, Romano E, Benelli G, Manetti M, Guiducci S, Ceccarelli C, Innocenti M, Carulli C, Civinini R, Morfini M, Matucci-Cerinic M, Ibba-Manneschi L.

J Rheumatol. 2012 Aug;39(8):1678-86. doi: 10.3899/jrheum.120370. Epub 2012 Jul 1.

PMID:
22753650
33.

Viscosupplementation in haemophilic arthropathy: a long-term follow-up study.

Carulli C, Civinini R, Martini C, Linari S, Morfini M, Tani M, Innocenti M.

Haemophilia. 2012 May;18(3):e210-4. doi: 10.1111/j.1365-2516.2011.02654.x. Epub 2011 Sep 22.

PMID:
21951693
34.

Ultrasound detects joint damage and bleeding in haemophilic arthropathy: a proposal of a score.

Melchiorre D, Linari S, Innocenti M, Biscoglio I, Toigo M, Cerinic MM, Morfini M.

Haemophilia. 2011 Jan;17(1):112-7. doi: 10.1111/j.1365-2516.2010.02380.x. Epub 2010 Nov 11.

PMID:
21070482
35.

Mortality and causes of death in Italian persons with haemophilia, 1990-2007.

Tagliaferri A, Rivolta GF, Iorio A, Oliovecchio E, Mancuso ME, Morfini M, Rocino A, Mazzucconi MG, Franchini M; Italian Association of Hemophilia Centers, Ciavarella N, Scaraggi A, Valdrè L, Tagariello G, Radossi P, Muleo G, Iannaccaro PG, Biasoli C, Vincenzi D, Serino ML, Linari S, Molinari C, Boeri E, La Pecorella M, Carloni MT, Santagostino E, Di Minno G, Coppola A, Rocino A, Zanon E, Spiezia L, Di Perna C, Marchesini M, Marcucci M, Dragani A, Macchi S, Albertini P, D'Incà M, Santoro C, Biondo F, Piseddu G, Rossetti G, Barillari G, Gandini G, Giuffrida AC, Castaman G.

Haemophilia. 2010 May;16(3):437-46. doi: 10.1111/j.1365-2516.2009.02188.x. Epub 2010 Feb 9.

PMID:
20148978
36.

A new severity score index for phenotypic classification and evaluation of responses to treatment in type I Gaucher disease.

Di Rocco M, Giona F, Carubbi F, Linari S, Minichilli F, Brady RO, Mariani G, Cappellini MD.

Haematologica. 2008 Aug;93(8):1211-8. doi: 10.3324/haematol.12379. Epub 2008 Jul 4.

37.

A modular total knee arthroplasty in haemophilic arthropathy.

Innocenti M, Civinini R, Carulli C, Villano M, Linari S, Morfini M.

Knee. 2007 Aug;14(4):264-8. Epub 2007 Jun 29.

PMID:
17601738
38.

High efficacy of combined therapy with pegylated interferon plus ribavirin in patients with hemophilia and chronic hepatitis C.

Mancuso ME, Rumi MG, Santagostino E, Linari S, Coppola A, Mannucci PM, Colombo M; Hepatitis Study Group of the Association of Italian Hemophilia Centers.

Haematologica. 2006 Oct;91(10):1367-71.

39.

Hemorrhagic symptoms and bleeding risk in obligatory carriers of type 3 von Willebrand disease: an international, multicenter study.

Castaman G, Rodeghiero F, Tosetto A, Cappelletti A, Baudo F, Eikenboom JC, Federici AB, Lethagen S, Linari S, Lusher J, Nishino M, Petrini P, Srivastava A, Ungerstedt JS.

J Thromb Haemost. 2006 Oct;4(10):2164-9.

40.

The discriminant power of bleeding history for the diagnosis of type 1 von Willebrand disease: an international, multicenter study.

Rodeghiero F, Castaman G, Tosetto A, Batlle J, Baudo F, Cappelletti A, Casana P, De Bosch N, Eikenboom JC, Federici AB, Lethagen S, Linari S, Srivastava A.

J Thromb Haemost. 2005 Dec;3(12):2619-26. Erratum in: J Thromb Haemost. 2006 Apr;4(4):925.

41.

Monitoring the bioavailability of FEIBA with a thrombin generation assay.

Váradi K, Negrier C, Berntorp E, Astermark J, Bordet JC, Morfini M, Linari S, Schwarz HP, Turecek PL.

J Thromb Haemost. 2003 Nov;1(11):2374-80.

42.

Factor VIII inhibitor-bypassing agents act by inducing thrombin generation and can be monitored by a thrombin generation assay.

Turecek PL, Váradi K, Keil B, Negrier C, Berntorp E, Astermark J, Bordet JC, Morfini M, Linari S, Schwarz HP.

Pathophysiol Haemost Thromb. 2003;33(1):16-22.

43.

A 6-month versus a 12-month surveillance for hepatocellular carcinoma in 559 hemophiliacs infected with the hepatitis C virus.

Santagostino E, Colombo M, Rivi M, Rumi MG, Rocino A, Linari S, Mannucci PM; Study Group of the Association of Italian Hemophilia Centers.

Blood. 2003 Jul 1;102(1):78-82. Epub 2003 Mar 20.

PMID:
12649165
44.

Identification of seven novel mutations of F8C by DHPLC.

Frusconi S, Passerini I, Girolami F, Masieri M, Linari S, Longo G, Morfini M, Torricelli F.

Hum Mutat. 2002 Sep;20(3):231-2.

PMID:
12203998
45.

Multivariate analysis of factors influencing quality of life and utility in patients with haemophilia.

Trippoli S, Vaiani M, Linari S, Longo G, Morfini M, Messori A.

Haematologica. 2001 Jul;86(7):722-8.

46.

Identification and characterization of a bipotent (erythroid and megakaryocytic) cell precursor from the spleen of phenylhydrazine-treated mice.

Vannucchi AM, Paoletti F, Linari S, Cellai C, Caporale R, Ferrini PR, Sanchez M, Migliaccio G, Migliaccio AR.

Blood. 2000 Apr 15;95(8):2559-68.

PMID:
10753835
47.

Increased expression of the distal, but not of the proximal, Gata1 transcripts during differentiation of primary erythroid cells.

Vannucchi AM, Linari S, Lin CS, Koury MJ, Bondurant MC, Migliaccio AR.

J Cell Physiol. 1999 Sep;180(3):390-401.

PMID:
10430179
48.

Evaluation of breast tumour cell contamination in the bone marrow and leukapheresis collections by RT-PCR for cytokeratin-19 mRNA.

Vannucchi AM, Bosi A, Glinz S, Pacini P, Linari S, Saccardi R, Alterini R, Rigacci L, Guidi S, Lombardini L, Longo G, Mariani MP, Rossi-Ferrini P.

Br J Haematol. 1998 Dec;103(3):610-7.

PMID:
9858208
49.

Coexpression of erythroid and megakaryocytic genes in acute erythroblastic (FAB M6) and megakaryoblastic (FAB M7) leukaemias.

Linari S, Vannucchi AM, Ciolli S, Leoni F, Caporale R, Grossi A, Pagliai G, Santini V, Paoletti F, Ferrini PR.

Br J Haematol. 1998 Sep;102(5):1335-7.

PMID:
9753066
50.

Constitutive and inducible expression of megakaryocyte-specific genes in Friend erythroleukaemia cells.

Vannucchi AM, Linari S, Cellai C, Koury MJ, Paoletti F.

Br J Haematol. 1997 Dec;99(3):500-8.

PMID:
9401056

Supplemental Content

Loading ...
Support Center